Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AstraZeneca, breast cancer
AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
AstraZeneca drug fails to extend lives of breast cancer patients
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030.
AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a setting in which Gilead’s rival Trodelvy significantly improved OS in a prior late-phase study.
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free survival endpoint,
AstraZeneca and Daiichi Suffer New Setback With Mixed Breast Cancer Drug Results
AstraZeneca Plc said an experimental cancer drug it’s developing with Daiichi Sankyo Co. did not help breast cancer patients live longer than chemotherapy.
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.
AstraZeneca and Daiichi Sankyo report data from Phase III breast cancer trial
AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab deruxtecan (Dato-DXd) for breast cancer. The trial compared Dato-DXd to the investigator's choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive,
3h
AstraZeneca: Buy This Big Pharma Stock At A Discount Now
AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...
devdiscourse
2h
Health Roundup: US Donates 1M Mpox Vaccines, AstraZeneca Disappoints in Breast Cancer Trial, Novo Faces Scrutiny
This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...
18h
AstraZeneca PLC ADR underperforms Monday when compared to competitors
The AstraZeneca PLC ADR AZN slipped 1.58% to $77.14 Monday, on what proved to be an all-around great trading session for the ...
23h
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...
moneycontrol.com
14h
Stock Radar: ONGC, Reliance, PNB, AstraZeneca, GR Infra, BGR Energy, Arkade Developers, Coal India in focus on Tuesday
Let's catch up on the latest
news
from the stock market. From significant investments to major deals, fund raising and ...
23h
AstraZeneca falls Monday, underperforms market
AstraZeneca PLC AZN shares dropped 1.66% to £115.84 Monday, on what proved to be an all-around great trading session for the ...
India Infoline
2h
AstraZeneca Pharma Surges on CDSO Approval for Durvalumab in India
AstraZeneca Pharma India has received approval from the CDSO for the import, sale, and distribution of Durvalumab.
cnbctv18
5h
AstraZeneca shares rally 13%, hit record high as firm gets nod for cancer drug
Astrazeneca Pharma India has received CDSO's (Central Drugs Standard Control Organisation) nod for the import of Durvalumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
flu vaccine
Dow Jones Industrial Average
Daiichi Sankyo
Trade
Blood Cancer Awareness Month
Feedback